PMID- 18602599
OWN - NLM
STAT- MEDLINE
DCOM- 20081017
LR  - 20181201
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 18
IP  - 7
DP  - 2008 Jul
TI  - [Targeted therapy for locally advanced and/or metastatic bladder cancer].
PG  - 407-17
LID - 10.1016/j.purol.2008.04.020 [doi]
AB  - Cancer is a complex disease characterized by a multitude of molecular and genetic 
      abnormalities affecting cell proliferation and differentiation, apoptosis, and 
      mobility (invasion). Each of these alterations represents a potential target for 
      the development of targeted therapy. These new therapies inhibit cell growth and 
      are said to be "cytostatic" in contrast with conventional "cytotoxic" 
      chemotherapy. As a result of a better understanding of the molecular biology of 
      bladder cancers, various signalling pathways involved in both carcinogenesis and 
      tumour progression have been defined, and some of the key molecules in these 
      pathways have been isolated and can be used as prognostic markers and as 
      potential therapeutic targets. Locally advanced, and/or metastatic bladder 
      cancer, is characterized by mutations of the p53 and retinoblastoma (Rb) genes, 
      regulators of the cell cycle, which interact with the Ras-mitogen activated 
      protein kinase (MPAK) transduction pathway. Overexpression of tyrosine kinase 
      receptors, including EGFR, VEFGR and HER2/neu, is correlated with tumour 
      progression and activation of the phosphatidyl-inositol-3 kinase (PI-3K) pathway 
      is involved in tumour invasion and inhibition of apoptosis. Due to their 
      molecular heterogeneity, optimal targeted therapy of bladder cancers will require 
      the combined use of several molecules. Modulation of signalling pathways by these 
      new molecules can restore chemosensitivity to cytotoxic drugs, which can then be 
      associated with targeted therapy.
FAU - Wallerand, H
AU  - Wallerand H
AD  - Service d'Urologie, CHU Pellegrin la Tripode, Universite Bordeaux-II 
      Victor-Segalen, Place Amelie-Raba-Leon, Bordeaux, France. 
      herve.wallerand@chu-bordeaux.fr
FAU - Robert, G
AU  - Robert G
FAU - Bernhard, J-C
AU  - Bernhard JC
FAU - Ravaud, A
AU  - Ravaud A
FAU - Ferriere, J-M
AU  - Ferriere JM
LA  - fre
PT  - Comparative Study
PT  - Journal Article
PT  - Review
TT  - Les therapeutiques ciblees du cancer de vessie localement avance et/ou 
      metastatique.
DEP - 20080626
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Quinazolines)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - IOW153004F (lonafarnib)
RN  - P188ANX8CK (Trastuzumab)
RN  - S65743JHBS (Gefitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Antibiotics, Antineoplastic/administration & dosage/therapeutic use
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Bevacizumab
MH  - Disease Progression
MH  - Erlotinib Hydrochloride
MH  - Gefitinib
MH  - *Genetic Therapy
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/therapeutic use
MH  - Mutation
MH  - Piperidines/administration & dosage/therapeutic use
MH  - Protein Kinase Inhibitors/administration & dosage/*therapeutic use
MH  - Pyridines/administration & dosage/therapeutic use
MH  - Quinazolines/administration & dosage/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Signal Transduction
MH  - Sirolimus/administration & dosage/therapeutic use
MH  - Targeted Gene Repair
MH  - Trastuzumab
MH  - Urinary Bladder Neoplasms/*drug therapy/*genetics/secondary
RF  - 32
EDAT- 2008/07/08 09:00
MHDA- 2008/10/18 09:00
CRDT- 2008/07/08 09:00
PHST- 2008/01/17 00:00 [received]
PHST- 2008/04/22 00:00 [revised]
PHST- 2008/04/23 00:00 [accepted]
PHST- 2008/07/08 09:00 [pubmed]
PHST- 2008/10/18 09:00 [medline]
PHST- 2008/07/08 09:00 [entrez]
AID - S1166-7087(08)00183-8 [pii]
AID - 10.1016/j.purol.2008.04.020 [doi]
PST - ppublish
SO  - Prog Urol. 2008 Jul;18(7):407-17. doi: 10.1016/j.purol.2008.04.020. Epub 2008 Jun 
      26.